ApoE 2/2
UKBi011-A-2
General
Cell Line |
|
| hPSCreg name | UKBi011-A-2 |
| Cite as: | UKBi011-A-2 (RRID:CVCL_VN45) |
| Alternative name(s) |
ApoE 2/2
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
BIONi010-C-3 (BIONi010-C ApoE KO #KO30 P30) BIONi010-C-2 (BIONi010-C ApoE E3/E3 #H8 P32) BIONi010-C-4 (BIONi010-C ApoE E4/E4 #B44 P27) BIONi010-C-6 (BIONi010-C ApoE E2/E2) BIONi037-A-2 (BIONi037-A ApoE2/2 #M10-7) BIONi037-A-3 (BIONi037-A ApoE3/4 #P10-22) BIONi037-A-4 (BIONi037-A ApoE4/4 #I10-53) BIONi037-A-1 (16423 ApoE KO) |
| Last update | 3rd July 2024 |
| Notes | This line is part of a set of isogenic APOE lines based on the iPS cell line UKBi011-A. The set comprises the following APOE genotypes: • UKBi011-A-1 (APOE KO) • UKBi011-A-2 (APOE 2/2) • UKBi011-A-3 (APOE 3/3) • UKBi011-A-4 (APOE 3/4) • UKBi011-A (APOE 4/4) A DNA SNP array revealed no larger chromosomal aberrations to be reported. Other isogenic ApoE cell line cohorts are also available, generated from BIONi010-C, BIONi037-A and STBCi006-A. |
| User feedback | |
Provider |
|
| Generator |
Bioneer (BION)
Contact:
Bioneer (BION) |
| Owner | Bioneer (BION) |
| Distributors | |
| Derivation country | Denmark |
External Databases |
|
| BioSamples | SAMEA104243175 |
| Cellosaurus | CVCL_VN45 |
| Wikidata | Q98133951 |
General Information |
|
| Publications |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasia, German |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA104132641 |
Ethics
Also have a look at the ethics information for the parental line
UKBi011-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
UKBi011-A.
|
|
| Passage number reprogrammed | 26 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 18 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SSEA-1 |
No |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|||||
| SSEA-1 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.